Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.41 |
| ▸ | OXTR | P30559 | 2/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.41 |
| ▸ | APLNR | P35414 | 4/20 | 0.41 |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 4/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697833 | 1.00 | ITGB3 (0.42) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL29816248 | 0.96 | AVPR1A (0.43) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL30697847 | 0.96 | AVPR1A (0.43) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL30697801 | 0.96 | AVPR1A (0.43) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL29816712 | 0.96 | AVPR1A (0.43) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL30697813 | 0.96 | AVPR1A (0.43) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL30697831 | 0.96 | AVPR1A (0.43) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL30697800 | 0.96 | AVPR1A (0.43) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL30697806 | 0.96 | AVPR1A (0.43) | ITGB3ITGA2BAVPR2OXTRAVPR1A | |
| SCHEMBL31135243 | 0.92 | ITGB3 (0.39) | ITGB3ITGA2BAVPR2OXTRAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-11426440-B2 | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | SUSTAIN HOLDINGS, LLC (US) | 2022-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | COL1A1, COL2A1, COL14A1 | ITGB3 619/4885ITGA2B 1297/4885AVPR2 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.